StockData
Collegium Pharmaceutical, Inc logo

Collegium Pharmaceutical, Inc (COLL) stock

COLLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/3045% below fair value
$24.81+0.34 (+1.39%)

Close on Nov 11, 2026Market cap $807.71MP/E 24.8Yield –

Earnings

Collegium Pharmaceutical's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 25, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$216.30M
+3.3% on a year earlier
adjusted earnings per share, Q3 FY2026
$1.96
$2.25 a year earlier
Latest guidance
Issued
Nov 5, 2026 · 4 items

Quarterly results

Revenue and earnings per share from each of Collegium Pharmaceutical's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 31, 2026Feb 25, 2027Expected–––––
Q3 FY2026ended Sep 30, 2026Nov 5, 2026before the open$216.30M+3.3%$0.60$1.96Release
Q2 FY2026ended Jun 30, 2026Aug 6, 2026before the open$199.90M+6.3%-$0.46$1.92Release
Q1 FY2026ended Mar 31, 2026May 7, 2026before the open$193.50M+8.8%$0.40$1.76Release
Q4 FY2025ended Dec 31, 2025Feb 26, 2026before the open$205.40M+12.9%$0.46$2.04Release
Q3 FY2025ended Sep 30, 2025Nov 6, 2025before the open$209.40M+31.5%$0.84$2.25Release
Q2 FY2025ended Jun 30, 2025Aug 7, 2025before the open$188.00M+29.4%––Release
Q1 FY2025ended Mar 31, 2025May 8, 2025after the close$177.80M+22.7%$0.07$1.49Release
Q4 FY2024ended Dec 31, 2024Feb 27, 2025after the close$181.90M+21.5%$0.36$1.75Release
Q3 FY2024ended Sep 30, 2024Nov 7, 2024after the close$159.30M+16.5%$0.27$1.61Release
Q2 FY2024ended Jun 30, 2024Aug 8, 2024after the close$145.30M+7.2%$0.52$1.62Release
Q1 FY2024ended Mar 31, 2024May 9, 2024after the close$144.90M+0.1%$0.71$1.45Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Collegium Pharmaceutical's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
AZSTARYS Revenue, NetGAAPFY2026$65.00M – $75.00M––Nov 5, 2026
Product Revenues, NetFY2026$825.00M – $855.00M$805.00M – $825.00MRaisedAug 6, 2026
Adjusted EBITDAnon-GAAPFY2026$445.00M – $470.00M––Nov 5, 2026
Adjusted EBITDAnon-GAAPFY2026$445.00M – $470.00M$455.00M – $475.00MLoweredAug 6, 2026

Guidance vs results

The last range Collegium Pharmaceutical gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025Revenue$775.00M – $785.00M$780.60MΣ4QWithin range

Guidance history

Every forecast Collegium Pharmaceutical put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 5, 2026Adjusted EBITDAFY2026$445.00M – $470.00M–
Nov 5, 2026AZSTARYS Revenue, NetFY2026$65.00M – $75.00M–
Nov 5, 2026JORNAY PM Revenue, NetFY2026$190.00M – $200.00M–
Nov 5, 2026Product Revenues, NetFY2026$825.00M – $855.00M–
Aug 6, 2026Adjusted EBITDAFY2026$445.00M – $470.00MLowered
Aug 6, 2026Product Revenues, NetFY2026$825.00M – $855.00MRaised
Aug 6, 2026JORNAY PM Revenue, NetFY2026$190.00M – $200.00MLowered
Aug 6, 2026AZSTARYS Revenue, NetFY2026$65.00M – $75.00MLowered
Feb 26, 2026Adjusted EBITDAFY2026$455.00M – $475.00MNew
Feb 26, 2026Product Revenues, NetFY2026$805.00M – $825.00MNew
Feb 26, 2026Jornay PM Revenue, NetFY2026$190.00M – $200.00MLowered
Nov 6, 2025Adjusted EBITDAFY2025$460.00M – $470.00MNew
Nov 6, 2025Adjusted Operating Expenses (Excluding Stock-Based Compensation)FY2025$235.00M – $240.00MNew
Nov 6, 2025Product Revenues, NetFY2025$775.00M – $785.00MNew
Nov 6, 2025Jornay PM Revenues, NetFY2025$145.00M – $150.00MLowered
Aug 7, 2025adjusted EBITDAFY2025+12%New
Aug 7, 2025Adjusted EBITDAFY2025$440.00M – $455.00MNew
Aug 7, 2025full-year revenueFY2025+19%New
Aug 7, 2025Product Revenues, NetFY2025$745.00M – $760.00MRaised
Aug 7, 2025Jornay PM net revenueFY2025$140.00M – $145.00MLowered

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Collegium Pharmaceutical filed with the SEC as exhibits to Form 8-K or 6-K

  1. Collegium Reports Third Quarter 2026 Financial Results; Reaffirms 2026 Guidance
    Results
  2. Quarterly results release
    Results
  3. Collegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company Progress
    Results
  4. Quarterly results release
    Results
  5. Collegium Completes Acquisition of AZSTARYS ®
    Update
  6. Collegium Reports First Quarter 2026 Financial Results and Highlights Recent Company Progress
    Results
  7. Quarterly results release
    Results
  8. Collegium to Acquire AZSTARYS® from Corium
    Update
  9. 8-K exhibit EX-99.2
    Update
  10. Collegium Reports Fourth Quarter and Full-Year 2025 Financial Results
    Results
  11. Quarterly results release
    Results
  12. Collegium Provides 2026 Financial Guidance and
    Update
  13. January 2026 | Nasdaq: COLL
    Update
  14. Announces the Closing of $980 Million Syndicated Credit Facility
    Update
  15. Collegium Reports Third Quarter 2025 Financial Results; Raises 2025 Guidance
    Results

See a number that looks wrong?